Natera (NASDAQ:NTRA) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report issued on Tuesday.
Several other equities research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Natera from a “buy” rating to a “hold” rating in a research note on Thursday, October 26th. Morgan Stanley reaffirmed an “overweight” rating and set a $16.00 price target (up from $13.00) on shares of Natera in a research note on Friday, October 6th. Canaccord Genuity reaffirmed a “buy” rating and set a $15.00 price target on shares of Natera in a research note on Tuesday, November 14th. Cowen reaffirmed a “buy” rating and set a $12.00 price target on shares of Natera in a research note on Thursday, December 21st. Finally, Robert W. Baird reaffirmed a “buy” rating on shares of Natera in a research note on Tuesday, October 24th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. Natera currently has an average rating of “Hold” and a consensus price target of $14.50.
Natera (NTRA) opened at $11.59 on Tuesday. The company has a current ratio of 1.85, a quick ratio of 1.75 and a debt-to-equity ratio of 2.43. Natera has a twelve month low of $7.35 and a twelve month high of $14.76. The firm has a market cap of $642.54, a PE ratio of -4.73 and a beta of 2.07.
Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, November 8th. The medical research company reported ($0.51) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.04). Natera had a negative return on equity of 197.09% and a negative net margin of 62.34%. The firm had revenue of $56.66 million for the quarter, compared to analyst estimates of $55.31 million. During the same period in the prior year, the business earned ($0.50) earnings per share. Natera’s revenue for the quarter was up 5.1% on a year-over-year basis. equities research analysts anticipate that Natera will post -2.15 earnings per share for the current fiscal year.
Institutional investors have recently added to or reduced their stakes in the business. Tygh Capital Management Inc. acquired a new stake in shares of Natera during the 3rd quarter worth about $2,794,000. Macquarie Group Ltd. boosted its stake in shares of Natera by 112.3% during the 2nd quarter. Macquarie Group Ltd. now owns 1,061,880 shares of the medical research company’s stock worth $11,532,000 after purchasing an additional 561,659 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Natera by 12.6% in the second quarter. Vanguard Group Inc. now owns 2,261,052 shares of the medical research company’s stock worth $24,555,000 after acquiring an additional 253,344 shares during the last quarter. Northern Trust Corp boosted its position in shares of Natera by 21.0% in the second quarter. Northern Trust Corp now owns 352,808 shares of the medical research company’s stock worth $3,831,000 after acquiring an additional 61,226 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its position in shares of Natera by 20.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 109,594 shares of the medical research company’s stock worth $1,191,000 after acquiring an additional 18,970 shares during the last quarter. 66.46% of the stock is currently owned by institutional investors.
COPYRIGHT VIOLATION WARNING: “Natera (NTRA) Lifted to Hold at BidaskClub” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://www.dispatchtribunal.com/2018/01/30/natera-ntra-lifted-to-hold-at-bidaskclub.html.
Natera, Inc is a diagnostics company. The Company is engaged in the discovery, development and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Horizon Carrier Screening to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier’s children; Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle to select embryos with the probability of becoming healthy children; Anora Products of Conception test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing, to determine paternity by analyzing the fragments of fetal deoxyribonucleic acid in a pregnant mother’s blood and a blood sample from the alleged father(s).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.